LABORIE completed its acquisition of Mediwatch Plc, a manufacturer and distributor of Urology and GI diagnostic products, including Urodynamics systems and disposables, bladder scanners, uroflowmeters, Pelvic Floor Biofeedback equipment, Anorectal Manometry systems and PSA Test equipment and disposables. The transaction was effective as of January 27, 2014.
“This acquisition further strengthens our foundation in Pelvic Muscle Rehabilitation and GI diagnostics by combining two market leaders in Urology and GI diagnostic products” stated Brian Ellacott, LABORIE President and CEO. “The combined resources of Mediwatch Plc. and LABORIE will allow us to accelerate our investments in development of innovative products, provide more comprehensive sales and customer service, as well as provide superior after-sales service to all of our global customers.”
Investec Bank plc and Raymond James & Associates, Inc., served as financial advisors to LABORIE. DWF LLP and Kirkland & Ellis LLP served as legal advisor.
LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in the UK at NHS Trust on June 11, 2021 by Dr. Pareeta Patel and Professor. Nick Watkin.
Laborie Medical Technologies Inc. (LABORIE), a leading diagnostic and therapeutic medical technology company, today announced the first Optilume® procedures were performed in Mannheim, Germany on January 22, 2021 by Dr. Georgi Tosev (Mannheim Urology).
Transaction demonstrates LABORIE’s commitment to providing innovative solutions to urologists globally LABORIE to invest $15 million in Urotronic Series C financing LABORIE secures option to acquire Urotronic’s Optilume™ technology